SBIA
ACOR

Sheaff Brock Investment Advisors’s Acorda Therapeutics ACOR Stock Holding History

Sheaff Brock Investment Advisors’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-208
Closed -$13K – 516
2020
Q3 		$13K Hold
208
– – ﹤0.01% 460
2020
Q2 		$18K Buy
+208
New +$22K ﹤0.01% 449

Other funds holding ACOR

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Sheaff Brock Investment Advisors's ACOR Position: Q4 2020 in Review

Sheaff Brock Investment Advisors sold out of Acorda Therapeutics (ACOR) in Q4 2020, closing a stake of 208 shares — an estimated $13K sold.

Sheaff Brock Investment Advisors first reported a position in ACOR in Q2 2020 and held it in 2 quarters. The position peaked at $18K in Q2 2020. 47 funds tracked by Wall St. Rank hold ACOR as of Q4 2020.

  • Sheaff Brock Investment Advisors reported no remaining Acorda Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Sheaff Brock Investment Advisors sold 208 Acorda Therapeutics shares in Q4 2020, an estimated $13K.
  • Sheaff Brock Investment Advisors first reported a position in Acorda Therapeutics in Q2 2020 and held it in 2 quarters.
  • Sheaff Brock Investment Advisors's Acorda Therapeutics position peaked at $18K in Q2 2020.
  • 47 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q4 2020.

Based on Sheaff Brock Investment Advisors's 13F filing for Q4 2020, filed 1 Feb 2021.